Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Journal of Dental Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sakoda, K.
Right arrow Articles by Izumi, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sakoda, K.
Right arrow Articles by Izumi, Y.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Statins
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Simvastatin Decreases IL-6 and IL-8 Production in Epithelial Cells

K. Sakoda1,*, M. Yamamoto2, Y. Negishi3, J.K. Liao4, K. Node5 and Y. Izumi1

1 Department of Periodontology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Sakuragaoka 8-35-1, Kagoshima 890-8544, Japan;
2 Department of Periodontology, Showa University Dental School, Tokyo, Japan;
3 School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan;
4 Vascular Medicine Unit, Cardiovascular Division, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA; and
5 Department of Cardiovascular & Renal Medicine, Saga University Faculty of Medicine, Saga, Japan


Figure 1
View larger version (16K):
[in this window]
[in a new window]

 
Figure 1. Dose-dependent effects of simvastatin on KB cells. (A) Cellular expression of IL-6 and IL-8 is shown in cultures after treatment with the indicated concentrations of simvastatin for 7 hrs, and/or IL-1{alpha} (1 ng/mL) for the last 5 of these hrs. Data are expressed as means ± SD (n = 4). *P < 0.01 and **P < 0.001 vs. control (treated with IL-1{alpha}). (B) Evaluation of cytotoxicity from simvastatin according to release of LDH into medium was carried out after 24 hrs of culture. LC, low control (medium alone); HC, high control (1% Triton X100).

 

Figure 2
View larger version (20K):
[in this window]
[in a new window]

 
Figure 2. Reversal of inhibitory effect of simvastatin on KB cells by co-treatment with downstream metabolites of HMG-CoA reductase. (A) Inhibitory effects of simvastatin (10–6 M) on KB cells were reversed by co-treatment with mevalonate (10–4 M) or GGPP (5 x 10–6 M), but not with FPP (5 x 10–6 M). Data are expressed as means ± SD (n = 4). *P < 0.001 vs. control (treated with IL-1{alpha}). (B) Schematic representation of the mevalonate pathway. Statins block conversion of HMG-CoA to mevalonate. This leads to reduced synthesis of cholesterol and decreased prenylation of proteins such as small GTPases. Isopentenyl-PP, isopentenyl pyrophosphate; Geranyl-PP, geranyl pyrophosphate.

 

Figure 3
View larger version (8K):
[in this window]
[in a new window]

 
Figure 3. Suppression of NF-{kappa}B and AP-1 activity in IL-1{alpha}-stimulated KB cells by simvastatin (10–6 M). KB cells were transiently co-transfected with pNF-{kappa}B-luc or pAP-1-luc, together with pCMV-βgal. The cells were analyzed 48 hrs later, with five-hour stimulation with IL-1{alpha} (1 ng/mL). All results were normalized for transfection efficiency using expression of β-galactosidase. Data are expressed as means ± SD (n = 4). *P < 0.001 vs. control (treated with IL-1{alpha}).

 

Figure 4
View larger version (15K):
[in this window]
[in a new window]

 
Figure 4. Effects of Rho family GTPases on IL-1{alpha}-mediated transactivation of NF-{kappa}B and AP-1. (A) IL-1{alpha}-induced NF-{kappa}B and AP-1 promoter activity of the transient transfectants of N17Rac1 was greatly inhibited, and IL-1{alpha}-induced NF-{kappa}B and AP-1 promoter activities of transiently transfected cells (N17Cdc42 and N19RhoA) also were inhibited. Mock, transient transfectants of empty vector. Data represent means ± SD (n = 4). *P < 0:01 and **P < 0.001 vs. control (mock with IL-1{alpha}). (B) Model depicting contributions of Rho family GTPases to NF-{kappa}B and AP-1 activation by IL-1. Rho, Rho family GTPases; GG-Rho, geranylgeranylated Rho family GTPases.

 

Journal of Dental Research, Vol. 85, No. 6, 520-523 (2006)
DOI: 10.1177/154405910608500608


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?